425: Strive to Acquire Semler Scientific in All-Stock Merger

Strive, Inc. announced an agreement to acquire Semler Scientific, Inc. in an all-stock transaction, with Semler Scientific becoming a wholly-owned subsidiary.

Summary

• Strive, Inc. entered into an Agreement and Plan of Merger with Semler Scientific, Inc. on September 22, 2025.
• A newly formed subsidiary of Strive, Merger Sub, will merge with Semler Scientific, with Semler Scientific surviving as a wholly-owned subsidiary of Strive.
• Immediately following the initial merger, the surviving Semler Scientific entity will merge into a Delaware limited liability company, Second Merger Sub, which will survive as a direct, wholly-owned subsidiary of Strive.
• Each share of Semler Scientific common stock will be converted into the right to receive 21.05 shares of Strive Class A Common Stock.
• The transaction is intended to qualify as a reorganization for U.S. federal income tax purposes under Section 368(a) of the U.S. Internal Revenue Code.
• The Boards of Directors of both Strive and Semler Scientific unanimously approved the merger agreement.
• Outstanding options to purchase Semler Scientific common stock will be converted into options to purchase Strive Class A Common Stock, maintaining original terms and conditions, including vesting and exercisability, with certain acceleration provisions for non-employee directors or in case of termination without cause post-merger.

Sentiment

Score: 7

Explanation: The merger is a significant strategic move with unanimous board approval and an intent for tax-free reorganization, which are positive indicators. However, the inherent risks of integrating two distinct businesses, coupled with Strive's exposure to volatile digital assets like Bitcoin, introduce considerable execution and market risks. The potential for dilution from Strive's share issuance also warrants caution.

Positives

• The Boards of Directors of both Strive and Semler Scientific unanimously approved the merger agreement, indicating strong internal support for the transaction.
• The transaction is structured to qualify as a reorganization under Section 368(a) of the U.S. Internal Revenue Code, which can offer tax benefits to shareholders.
• Semler Scientific's non-employee directors will see immediate vesting acceleration of unvested options if their service continues through the closing date, providing a clear benefit.
• Semler Scientific employees whose employment is terminated without cause within six months post-merger will also have their unvested options immediately accelerate, offering a degree of protection.

Negatives

• Semler Scientific is obligated to pay a termination fee of $49 million (cash or Bitcoin) to Strive under specified circumstances, including a change in recommendation by its Board or if an alternative acquisition proposal is pursued within one year of termination.
• The merger is subject to customary closing conditions, including stockholder approvals and regulatory clearances, which introduce uncertainty and potential for non-consummation.
• Strive is not required to divest assets or businesses, enter into consent decrees, or take other actions that would constitute a 'Burdensome Condition' to resolve antitrust impediments, which could limit its flexibility in addressing regulatory concerns.

Risks

• The anticipated benefits of the proposed transaction, including cost savings and strategic gains, may not be realized when expected or at all.
• Changes in, or problems arising from, the implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets could adversely affect the combined company's future financial performance.
• General economic and market conditions, interest and exchange rates, monetary policy, and changes in laws and regulations and their enforcement could impact the combined entity.
• The integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The proposed transaction may be more expensive or take longer to complete than anticipated due to unexpected factors or events.
• Management's attention may be diverted from ongoing business operations and opportunities during the integration process.
• Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction will cause dilution to existing shareholders.
• Potential adverse reactions from Strive's or Semler Scientific's customers or changes to business or employee relationships could occur as a result of the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing could affect the value of the transaction.
• The outcome of any legal proceedings that may be instituted against Strive, Semler Scientific, or the combined company could be adverse.

Future Outlook

The merger is expected to yield strategic and financial benefits, including the successful integration of the combined businesses. However, these forward-looking statements are subject to various risks and uncertainties, such as the non-realization of anticipated benefits, potential difficulties in integration, and the impact of general economic and market conditions, particularly those related to Bitcoin and other digital assets.

Management Comments

• The Boards of Directors of both Strive and Semler Scientific unanimously approved the Agreement and Plan of Merger, determining it to be advisable, fair, and in the best interests of their respective companies and stockholders.
• Matthew Cole, Chief Executive Officer of Strive, Inc., and Eric Semler, Chairman of the Board of Semler Scientific, Inc., signed the merger agreement.

Industry Context

This acquisition represents a notable strategic move, as Strive, a company with stated Bitcoin treasury strategies and exposure to digital assets, is acquiring Semler Scientific, a medical device company known for its QuantaFlo product. This suggests either a diversification strategy for Strive into the healthcare sector or an intent to integrate Semler Scientific's operations and potentially its financial assets within Strive's broader digital asset-focused portfolio, creating a unique hybrid entity.

Management Changes

Corporate Governance

Stakeholder Impact

• **Semler Scientific Shareholders**: Will receive 21.05 shares of Strive Class A Common Stock for each Semler Scientific share, converting their investment into the combined entity.
• **Strive Shareholders**: Will experience dilution due to the issuance of new Class A Common Stock for the acquisition.
• **Semler Scientific Employees**: Will have their outstanding stock options converted into Strive options with similar terms; certain vesting accelerations apply for non-employee directors and in cases of termination without cause post-merger. They will also receive comparable compensation and benefits for 12 months post-closing and have 401(k) rollover opportunities.
• **Management (Eric Semler)**: Will transition from Chairman of Semler Scientific to a director on Strive's Board, subject to independence criteria.

Next Steps

• Strive will form a new Delaware corporation (Merger Sub) and a Delaware limited liability company (Second Merger Sub).
• Strive will deliver the duly executed Parent Stockholder Approval to Semler Scientific by September 24, 2025.
• The Company and Parent will jointly prepare and file a Registration Statement on Form S-4, including an Information Statement/Proxy Statement/Prospectus, with the SEC.
• The SEC must clear the Information Statement/Proxy Statement/Prospectus and declare the Registration Statement effective.
• Semler Scientific will convene a stockholder meeting to obtain the necessary Company Stockholder Approval.
• Strive Class A Common Stock to be issued in the merger must be approved for listing on Nasdaq.
• The merger will be consummated, followed by the Second Merger.
• Eric Semler, a director of Semler Scientific, will be appointed to Strive's Board of Directors, subject to Nasdaq independence criteria.
• Semler Scientific's 401(k) Plan will be terminated immediately prior to the Effective Time, unless otherwise directed by Strive, with provisions for employee rollover contributions.

Key Dates

Recommendation

The definitive merger agreement provides a clear path for Semler Scientific shareholders to convert their holdings into Strive Class A Common Stock. For Strive shareholders, the acquisition represents a strategic expansion, but successful integration and the performance of the combined entity, particularly given Strive's exposure to digital assets, will be key determinants of long-term value. The unanimous board approval and intent for a tax-free reorganization are positive, but the inherent risks of mergers and market volatility warrant a 'Hold' pending further clarity on integration execution and combined business performance.

Keywords

Strive, Semler Scientific, Merger, Acquisition, Stock-for-stock, Bitcoin, Medical Device, Corporate Reorganization, Nasdaq, ASST, QuantaFlo, SEC Filing